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On the basis of multidimensional and comprehensive
molecular characterization (including DNA methaly-
lation and copy number, RNA, and protein ex-
pression), we classified 894 renal cell carcinomas
(RCCs) of various histologic types into nine major
genomic subtypes. Site of origin within the nephron
was one major determinant in the classification, re-
flecting differences among clear cell, chromophobe,
and papillary RCC. Widespread molecular changes
associated with TFE3 gene fusion or chromatin mod-2476 Cell Reports 14, 2476–2489, March 15, 2016 ª2016 The Authorifier genes were present within a specific subtype
and spanned multiple subtypes. Differences in pa-
tient survival and in alteration of specific pathways
(including hypoxia, metabolism, MAP kinase, NRF2-
ARE, Hippo, immune checkpoint, and PI3K/AKT/
mTOR) could further distinguish the subtypes. Im-
mune checkpoint markers and molecular signatures
of T cell infiltrates were both highest in the subtype
associated with aggressive clear cell RCC. Differ-
ences between the genomic subtypes suggest that
therapeutic strategies could be tailored to each
RCC disease subset.s
INTRODUCTION
Renal cell carcinoma (RCC) represents a heterogeneous group
of cancers arising from the nephron. Different cancer types fall-
ing under the umbrella of RCC include clear cell, papillary, and
chromophobe, which represent on the order of 65%, 20%, and
5% of all RCC cases, respectively (Jonasch et al., 2014). In addi-
tion to these three major categories, several more rare subtypes
of RCC also exist, including clear cell papillary, mucinous tubular
and spindle cell carcinoma, multilocular cystic clear cell, tubulo-
cystic, thyroid-like follicular, acquired cystic kidney disease
associated, t(6;11) translocation (TFEB), and hybrid oncocy-
toma/chromophobe (Crumley et al., 2013; Shuch et al., 2015).
These various types of RCC have come to be defined on the ba-
sis of their histologic appearance, the presence of distinct driver
mutations, varying clinical course, and different responses to
therapy (Linehan and Rathmell, 2012). The premise that the
types of RCC represent different diseases entirely distinct from
each other is underscored by numerous molecular profiling
studies (Davis et al., 2014; Durinck et al., 2015; Higgins, 2006).
Recently, The Cancer Genome Atlas (TCGA) carried out sepa-
rate studies of the three major histologically defined types of
RCC—clear cell, chromophobe, and papillary—to comprehen-
sively profile each of them at the molecular level, uncovering in-
sights into the molecular basis of each disease (Davis et al.,
2014; Cancer Genome Atlas Research Network, 2013, 2015).
These molecular studies provided evidence of additional sub-
types existing within each major RCC type. In addition, specific
molecular aberrations could be identified in more than one
RCC type, such as the presence of chromatin modifier gene mu-
tations in a subset of both clear cell and papillary RCC. With the
recent conclusion of the data generation phase of TCGA, and
with additional TCGA RCC samples and profiling data being
made available since the earlier TCGA RCC studies, there is op-
portunity for systematic analyses of the entire TCGA RCC data-
set, allowing for comparisons and contrasts to bemade between
the different diseases represented, as well as a molecular exam-
ination of RCC cases that may be difficult to characterize in
terms of histology alone.
RESULTS
TCGA Cohort of 894 RCC Cases
TCGA collected a total of 894 primary RCC specimens (Table
S1). These specimens were divided among three different
TCGA-sponsored projects: ‘‘KIRC,’’ corresponding to the study
of clear cell RCC; ‘‘KICH,’’ corresponding to chromophobe RCC;
and ‘‘KIRP,’’ corresponding to papillary RCC. Of the 894 cases,
673 (446 KIRC, 66 KICH, and 161 KIRP) have been analyzed pre-
viously by TCGA in studies focusing on a specific histologic
RCC type (Davis et al., 2014; Cancer Genome Atlas Research
Network, 2013, 2015). As a result of pathology re-review or pre-
liminary molecular analysis, 49 cases (43 KIRC and 6 KIRP) were
removed from their respective studies (i.e., thesewere not part of
the above-mentioned 673 cases) because they showed irregu-
larities that might preclude their inclusion under the specific
RCC type associated with the project. For example, in the
above-mentioned KIRC study, molecular analysis flagged 61CellKIRC cases as suspected non-clear cell RCC, of which 45 had
pathology data available that were re-reviewed, confirming 18
cases as likely clear cell RCC with the others likely representing
chromophobe or another RCC disease type. In this present
study, as we were interested in all RCC subtypes, we included
all cases, regardless of the potential for mislabeling of histologic
designation in some instances. At the same time, we regarded
the TCGA project assignments of KIRC, KICH, and KIRP as
mostly, but not entirely, corresponding to their associated histo-
logic types, with the potential for rare RCC types or possible mis-
labeling to be revealed by molecular characterization.
Analysis of RCC Based on Single Molecular Data
Platform Reveals Widespread Differences Associated
with Histology
For the 894 RCC cases, data platforms for profiling of mRNA
expression, DNA methylation, DNA copy, microRNA (miRNA)
expression, and protein expression were each analyzed in an un-
supervised manner, allowing the RCC cases to associate with
cases showing similar global molecular patterns. For each plat-
form, cases segregated into groups closely aligned with the
designated histologic type. For example, in a clustered matrix
of inter-profile correlations involving the 888 RCCmRNA profiles
in our dataset, three major sample groups were evident, corre-
sponding to the TCGA projects of KIRC (clear cell RCC), KICH
(chomophobe RCC), and KIRP (papillary RCC) (Figure 1A). How-
ever, on the basis of mRNA sample profile, a subset of cases
were found to associate with a different histologic type from
that of their project designation; a notable example of this are
15 KIRC cases previously found to represent likely chromo-
phobe RCC cases (and which were therefore removed from
that study’s results) (Cancer Genome Atlas Research Network,
2013), almost all of which associated with the KICH group, as ex-
pected. In addition, subgroups within the KIRC and KIRP groups
in particular were also evident, with clusters of profiles having
somewhat higher correlations with each other as compared to
the other profiles within the project. We relied on formal analyt-
ical techniques such as ConsensusClusteringPlus (Wilkerson
and Hayes, 2010) to define these molecular subgroups existing
within the broader histologic types (see below).
Many of the molecular differences that exist among the clear
cell, chromphobe, and papillary RCC types could arise from their
respective cells of origin. Clear cell RCC is thought to arise from
cells in the proximal convoluted tubule, while chromophobe RCC
is thought to arise from intercalated cells in the distal convoluted
tubule of the nephron (Prasad et al., 2007). This theory is sup-
ported by TCGA’s analysis of clear cell RCC and chromophobe
RCC gene expression profiles in the context of an external
expression dataset of normal tissuemicrodissected from various
regions of the nephron (Cheval et al., 2012; Davis et al., 2014).
We re-examined this model using this combined set of 888
cases, and confirmed that clear cell RCC cases had expression
profiles most similar to the glomerulus and proximal nephron,
chromophobe RCC cases were most similar in expression to
the distal nephron, while papillary RCC cases were in general
most similar in expression to the proximal nephron (Figure 1B).
In the context of previous studies focusing on specific markers
by immunohistochemistry (Prasad et al., 2007), the different sitesReports 14, 2476–2489, March 15, 2016 ª2016 The Authors 2477
Figure 1. Analysis of RCC by Individual Data Platforms
(A) Correlation heatmap of gene expression data from 888 RCC cases of
various histologic types. Pearson’s correlation between each differential RCC
profile was calculated among 20,531 genes, with the correlation values then
clustered to show the global co-expression patterns between samples (red,
2478 Cell Reports 14, 2476–2489, March 15, 2016 ª2016 The Authorof the nephron being associated with specific RCC subsets
would be reflective of the different cell types located at each
nephron site.
Diverse DNA methylation patterns were evident both across
and within the histology-based subgroups (Figure 1C). Molec-
ular subtyping by DNA methylation platform revealed at least
ten different subtypes existing within our RCC cohort (Figures
S1A–S1C), including one subtype (consisting of 21 KIRC and
41 predominately ‘‘type 2’’ KIRP samples, papillary RCC hav-
ing two main subtypes by histology: type 1 and type 2) with
widespread DNA hypermethylation patterns and association
with poor patient outcome (Figures S1B and 1D), another sub-
type of chromophobe RCC cases, another subtype represent-
ing a mixture of cases from the three projects (n = 32), two
additional subtypes of papillary RCC cases, and four addi-
tional subtypes of clear cell RCC cases, two of which were en-
riched for BAP1 mutations and associated with poor patient
outcome (Figure S1C).
We usedGISTIC to identify recurrent focal somatic copy-num-
ber alterations, which yielded 13 regions of focal amplification
(q < 0.1) and 26 significant focal deletions (Figure S1D). Targeted
genomic regions and associated genes for copy loss included
3p26.3 (involving 130 genes including VHL), 3p21.2 (BAP1/
PBRM1/SETD2), 9p21.3 (CDKN2A/B), 10q23.31 (PTEN),
11q23.1 (SDHD), and 13q14.2 (RB1) and for copy gain 3q26.32
(PIK3CA), 5q35.1 (FGFR4/GNB2L1/SQSTM1), and 7q31.2
(MET). Unsupervised clustering of RCC cases based on copy-
alteration data could separate cases on the basis of histologic
classification (clear cell, chromophobe, and papillary), while
further distinguishing clear cell and papillary RCC having chro-
mosome 9p loss with a high degree of aneuploidy from other
RCC cases having few copy-number alterations (other than 3p
loss and 5q31 gain in the case of clear cell RCC). RCC subtypes
based on mRNA expression, protein expression, and miRNA
expression were also identified (Figures S1E–S1G), with signifi-
cant correspondence being observed among the various plat-
form-specific subgroupings (Figure S1H).high correlation or global similarity). KIRC, TCGA clear cell RCC project; KICH,
TCGA chromophobe project; KIRP, TCGA papillary project. Previously, mo-
lecular analysis and pathology re-review had flagged 15 KIRC cases as likely
representing chromophobe (ChRCC) and not clear cell RCC, as indicated.
(B) Heatmaps showing inter-sample correlations (red, positive) between
mRNA profiles of RCC (columns; TCGA data, arranged by project) and mRNA
profiles of kidney nephron sites (rows; dataset from Cheval et al., 2012). CCD,
kidney cortical collecting duct; CNT, kidney connecting tubule; CTAL, kidney
cortical thick ascending limb of Henle’s loop; DCT, kidney distal convoluted
tubule; Glom, kidney glomerulus; MTAL, kidney medullary thick ascending
limb of Henle’s loop; OMCD, kidney outer medullary collecting duct; S1/S3,
kidney proximal tubule. RCC samples previously flagged by TCGA as having
molecular or histologic features atypical of the project designation are indi-
cated (gray, not previously evaluated by TCGA).
(C) DNA methylation patterns corresponding to the mRNA profiles in (B),
featuring the top 2,000 genomic loci with the highest variability in methylation
patterns across tumors. Sample ordering the same for (B) and (C).
(D) Differences in patient overall survival associated with a tumor subtype
showing widespread DNA hypermethylation patterns. Left: KIRC cohort; right:
KIRP cohort. p values by log-rank test. Numbers of cases in represent patients
with survival data available.
See also Figure S1.
s
Multi-platform Analysis Uncovers Nine Major Genomic
Subtypes of RCC
Results from each of the individual data platforms analyzed (DNA
methylation, DNA copy alteration, mRNA expression, miRNA
expression, and protein expression) were consolidated to define
multi-platform-based RCC genomic subtypes. To provide an in-
tegrated level of assessment, subtype callsmade by the different
molecular platforms were combined by a ‘‘cluster of clusters
analysis’’ (COCA) (Hoadley et al., 2014) approach to form 13
different integrated subtypes (Figures S2A–S2C). On the basis
of overall similarity in RNA expression patterns, four of the 13
COCA-based subtypes were then further grouped together
with similar clusters (Figure S2D; Table S2), resulting in a consol-
idated set of nine molecular-based RCC subtypes.
The nine genomic subtypes of RCC (Figure 2A) included three
different subtypes of predominantly clear cell RCC cases, desig-
nated here as ‘‘CC-e.1’’ (n = 106), ‘‘CC-e.2’’ (n = 257), and
‘‘CC-e.3’’ (n = 140, the ‘‘e’’ signifying ‘‘enriched for clear cell
cases’’ in each instance); four different subtypes of predomi-
nantly papillary RCC cases—‘‘P-e.1a’’ (n = 135), ‘‘P-e.1b’’ (n =
72), ‘‘P-e.2’’ (n = 53), and ‘‘P.CIMP-e’’ (n = 25, the names signi-
fying type-1-enriched group a, type-1-enriched group b, type-
2-enriched, and papillary CIMP-enriched, respectively, CIMP
signifying the ‘‘CpG island methylator phenotype’’ group uncov-
ered in TCGA’s KIRP study); one subtype of predominantly
chromophobe cases (‘‘Ch-e,’’ n = 78), including 11 KIRC cases
re-reviewed by pathology and thought to represent chromo-
phobe instead of clear cell RCC; and one subtype of mixed
cases from the three projects (14 KIRC, 4 KICH, and 10 KIRP).
When considering the 663 RCC cases that were analyzed previ-
ously by TCGA, not excluded by pathology re-review, and not
associated with the ‘‘mixed’’ subtype, 647 (98%) associated
with a genomic subtype that was aligned with the assumed his-
tologic type according to project designation. Of the 28 cases of
the ‘‘mixed’’ molecular subtype, a category that appeared
outside of the three major histologic classifications, 16 had pre-
viously been studied by TCGA, with ten of these (seven KIRC and
three KIRP) eventually being excluded from the earlier studies for
having molecular or histologic features appearing inconsistent
with its project designation.
Individual molecular features were informative in distinguish-
ing the RCC genomic subtypes from each other. Of the clear
cell-enriched subtypes, CC-e.2, CC-e.3, and CC-e.1 cases
were associated with better, worse, and intermediate patient
survival, respectively (Figure 2B); widespread copy alterations,
including frequent loss of CDKN2A, represented a key distin-
guishing feature of the two more aggressive subtypes (Fig-
ure S3A). As compared to CC-e.2 tumors, CC-e.3 tumors also
showed higher expression of cell-cycle genes and hypoxia-
related genes and markers of epithelial-mesenchymal transition
(EMT). Of the 62 RCC cases showing hypermethylation (Figures
1C, S1A, and S3B), 24 were classified as P.CIMP-e and were en-
riched for cases of hereditary papillary RCC and characterized in
part by CDKN2A copy loss or silencing (involving 19/24 cases)
and by loss of FH expression with high cell-cycle gene expres-
sion, 18 were classified as P-e.2 (with CDKN2A alterations in 4
cases), and 17 were classified as CC-e.3. Of the papillary
RCC-enriched subtypes P-e.1a, P-e.2, and P.CIMP-e wereCellassociated with better, intermediate, and worse patient survival,
respectively (Figure 2C). P-e.1a and P-e.1-b tumors were asso-
ciated with papillary type 1 status by histology and with a high
frequency of 7q gains, while P-e.2 and P.CIMP-e tumors were
predominantly of type 2 histology. Patterns associated with
P-e.1b (both molecular- and survival-related) appeared some-
what intermediate between those associated with P-e.1a and
P-e.2; in a similar manner, CC-e.1 patterns appeared intermedi-
ate between those of CC-e.2 and CC-e.3.
The nine genomic subtypesmade across all TCGA RCC cases
showed high concordance with other subtype designations pre-
viously called for the same samples, on the basis of gene expres-
sion profiles or multi-platform analysis within the clear cell or
papillary RCC histologic types (Figure 2D). The previously re-
ported ccA and ccB clear cell RCC expression subtypes (Bran-
non et al., 2010) corresponded to our CC-e.2 (better prognosis)
and CC-e.3 (worse prognosis), respectively. Of the four mRNA-
expression-based subtypes, m1/m2/m3/m4, defined previously
in the original KIRC study, m1 and m3 overlapped with CC-e.2
and CC-e.3, respectively, while CC-e.1 overlapped significantly
with m2 and m4. Of our papillary RCC-enriched subtypes,
P-e.1a/1b, P-e.2, and P.CIMP-e corresponded to previous
KIRP subtypes c1 (type 1 enriched), c2a/c2b (type 2 enriched),
and CIMP, respectively.
Somatic Mutations and Genomic Rearrangements
across RCC Subtypes
Whole-exome sequencing of 856 RCC cases identified 20 genes
that demonstrated statistically significant recurrent rates ofmuta-
tion (Figure 3A; q < 0.1, MutSigCV) within all RCC, within RCC of
clear cell-enriched genomic subtypes (1/2/3), within Ch-e sub-
type, or within papillary-enriched RCC subtypes (1a/1b/2/
CIMP). The significance analysis was performed by restricting
themultiplehypothesis testing to344genessignificant inprevious
studies involving analysis of RCC exome data (Table S3), though
analysis of the entire exome did not yield additional candidate
novel drivers. Significantly aberrant genes includedVHL (mutated
inclear cellRCCcases),TP53, chromatinmodifiergenes (PBRM1,
SETD2, BAP1, ARID1A, MLL3, KDM5C, and SMARCB1), PI3K/
AKT/mTOR pathway genes (MTOR, PTEN, and PIK3CA), MET
(mutated in papillary RCC), Hippo pathway gene NF2, and
NRF2-ARE pathway gene NFE2L2. In addition, genes epigeneti-
cally silenced included VHL and CDKN2A (Figures 3A and S3B).
Assessment of geneswithin pathways demonstrated a high num-
ber of alterations involving chromatin modification (32.4% of
cases), SWI/SNF complex (30.6%), PI3K/AKT/mTOR (15.2%),
p53 (10.7%), NRF2-ARE (4.7%), and Hippo signaling (3.9%) (Fig-
ure 3B). Whole-genome analysis of 129 RCC cases (41 KIRC,
50 KICH, and 38 KIRP) identified an average of 25 genomic rear-
rangements per case (range 0–1,198), with P.CIMP-e tumors
showing a greater number of rearrangements on average as
compared to the other subtypes (Figure 3C; Table S4). In addition
to KICH cases previously showing kataegis and TERT-promoter-
associated structural variants (Davis et al., 2014), chromothripsis
was evident in a handful of cases associating with papillary
RCC-enriched subtypes (Figure 3D).
Genomic rearrangements in RCC may result in gene fusions
involving the nutrient-responsive transcription factor TFE3,Reports 14, 2476–2489, March 15, 2016 ª2016 The Authors 2479
Figure 2. Genomic Subtypes of RCC by Analysis of Multiple Data Platforms
(A) Integration of subtype classifications from five ‘‘omic’’ data platforms identified nine major RCC groups. Three of these subtypes—CC-e.1, CC-e.2, and
CC-e.3—are enriched for clear cell RCC cases; four other subtypes—P-e.1a, P-e.1b, P-e.2, and P.CIMP-e—are enriched for papillary RCC cases; one subtype,
Ch-e, is enriched for chromophobe RCC cases; and one subtype (‘‘mixed’’) is not enriched for any of the above. Each row in the top heatmap denotes mem-
bership within a specific subtype defined by the indicated data platform. The second heatmap below displays differential mRNA patterns for a set of genes that
help to distinguish between the nine subtypes (for each subtype, showing the top 100 genes most differentially in the given subtype versus the rest of the tumors,
with P-e.1b tumors showing patterns intermediate between P-e.1a and P-e.2). The third heatmap shows the top 2,000 genomic loci with the highest variability in
DNA methylation patterns across tumors. Specific molecular, clinical, copy-number, and gene expression features associated with one or more of the multi-
platform-based subtypes are shown toward the bottom.
(B) Differences in patient overall survival among the three genomic subtypes representing clear cell RCC (p < 1E-7, log-rank).
(C) Differences in patient overall survival among the four genomic subtypes representing papillary RCC (p < 1E-22). Numbers of cases in (B) and (C) represent
patients with survival data available.
(D) Significance of overlap between the subtype assignments made in the present study, with mRNA-based or multi-platform-based subtype assignments made
previously for a subset of cases. p values by one-sided Fisher’s exact test.
See also Figure S2 and Table S2.
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Figure 3. Somatic Mutations and Rearrangements in RCC
(A) By exome analysis (n = 856 RCC cases with available data), genes with statistically significant patterns of mutation in the TCGA RCC cohort (MutSigCV,
false discovery rate < 0.1, testing for 344 genes significant in previous studies involving analysis of RCC exome data), with mutation types. MutSigCV q-values
evaluate significance within all RCC, RCC of clear cell-enriched (‘‘CC-e’’) genomic subtypes (1/2/3), Ch-e RCC, or RCC of papillary-enriched (‘‘P-e’’) subtypes
(legend continued on next page)
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a member of the micropthalmia (MiT) family (Kauffman et al.,
2014). Of 759 TCGA RCC cases evaluated, 11 cases—5 KIRC
and 6 KIRP—harbored a TFE3 fusion. All 11 of these cases
were found within our P-e.2 (papillary Type 2-associated) sub-
type (Figure 3A), representing a significant enrichment (p <
1E-15, one-sided Fisher’s exact test). We identified a gene tran-
scription program associated with TFE3 gene fusions. Between
P-e.2 cases with TFE3 fusion versus other P-e.2 cases, 525
genes (411 high and 114 low with fusion) were differentially ex-
pressed with high significance (Figure 3E; Table S5; p < 0.001,
t test; FDR < 5%). Genes with high expression in TFE3 fusion
cases were enriched for those associated with plasma mem-
brane (120 with related GeneOntology term, p < 1E-9, one-sided
Fisher’s exact test), and 24 genes with low expression were
mitochondrion related (p < 1E-7). Two RCC cases were found
with a TFEB fusion, but these did not share the expression signa-
ture of the TFE3 fusion cases. The TFE3-associated transcrip-
tional signature would support the notion that RCC with TFE3
translocations represents a distinct disease entity.
Chromatin Modifier Gene Mutations and Associated
Molecular Alterations Common to Multiple RCC
Subtypes
Unsupervised pathway analysis using the MEMo algorithm
(Ciriello et al., 2012) identified mutually exclusive patterns of al-
terations targeting multiple histone acetyltransferases and com-
ponents of the SWI/SNF complex in 31% of RCC (Figure 4A),
with altered cases spanning clear cell- and papillary-associated
RCC subtypes. In clear cell RCC, mutations in the chromosome
3p chromatin modifiers PBRM1, SETD2, and BAP1, were each
associated with widespread alterations in gene transcription or
DNAmethylation (Pen˜a-Llopis et al., 2012; Cancer GenomeAtlas
Research Network, 2013). As chromatin modifier mutations in
these genes were also observed in papillary RCC, there was op-
portunity to identify differential effects common to both clear cell
and papillary RCC.Within our three clear cell RCC-enriched sub-
types, samples with mutations in PBRM1 were compared to
samples with wild-type PBRM1; similar analyses were carried
out for SETD2 and BAP1, with the same types of analyses also
carried out within our four papillary RCC-enriched subtypes.
Within both clear cell- and papillary-enriched groups, PBRM1
mutations,SETD2mutations, andBAP1mutations each resulted
in altered expression patterns of significant numbers of genes
(Figure S4A). In addition, the overlap between clear cell- and
papillary-associated gene sets was highly significant, yielding
on the order of hundreds of genes common to both, suggesting(1a/1b/2/CIMP). Panel on the right represents significance of enrichment (one-si
particular genomic subtype versus the other subtypes.
(B) Pathway-centric view of genemutations in RCC, involving key pathways and g
(Lawrence et al., 2014). Panel on the right represents significance of enrichment
within any particular genomic subtype versus the other subtypes.
(C) By whole-genome analysis (representing 50 KICH, 41 KIRC, and 38 KIRP cas
subtype. p values by t test on logged counts. Boxplot represents 5%, 25%, 50%
(D) KIRC and KIRP cases showing chromothripsis patterns. Genomic rearrangem
lines, inter-chromosomal events.
(E) Global consequences of TFE3 fusion within P-e.2 subtype. Heatmaps (involvin
P-e.2 with TFE3 fusion versus other P-e.2 (p < 0.001, t test; FDR < 5%). Selecte
See also Figure S3 and Tables S3, S4, and S5.
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ure 4B). In contrast to clear cell RCC, VHL mutations and 3p
loss of heterozygosity (LOH) are less common in papillary
RCC, suggesting that monoallelic mutations in these chromatin
modifiers can impact gene expression.
Using a similar approach applied to DNA methylation profiling
data, numerous changes could be associated with mutation in
either PBRM1 or SETD2, most changes involving increased
methylation (Figure 4B). Within the clear cell RCC-enriched
group, wild-type CC-e.3 tumors also shared many of the molec-
ular patterns associated with SETD2 orBAP1mutation; similarly,
within the papillary RCC-enriched group, wild-type P-e.2 and
P.CIMP-e tumors shared many patterns associated with
SETD2mutation (Figures 4B and S4B). The presence of the mu-
tation-associated molecular patterns in non-mutant RCC cases
suggests that in the absence of detectable mutations there are
post-transcriptional/translational mechanisms that functionally
converge on chromatin modifier-regulated genes. SETD2 muta-
tion and BAP1mutation have previously trended with worse pa-
tient survival in clear cell RCC (Hakimi et al., 2013; Kapur et al.,
2013). Across clear cell- and papillary-associated RCC subtypes
in TCGA cohort, worse survival was associated with SETD2
or BAP1 mutation, with their related gene transcriptional signa-
tures involving greater numbers of RCC cases and also being
predictive of worse outcome (Figures 4C and S4C–S4E).
Through integration of DNA methylation and gene expression
data, significant numbers of genes were found with associated
increased CpG island methylation and decreased expression
in RCC cases harboring mutation of a specific chromatin modi-
fier gene (Figure 4D); coordinate methylation and expression
changes associated with SETD2 mutation in particular were en-
riched for genes located in 19q13, a region frequently deleted in
other cancer types (Zack et al., 2013).
Pathways Showing Differential Activity between RCC
Subtypes Include PI3K/AKT/mTOR and Immune
Checkpoint
In addition to the differences between the genomic subtypes
noted above regarding cell cycle, hypoxia, and EMT (Figure 2A,
bottom), other pathways that were altered in different subtypes
included oxidative phosphorylation, MAP kinase, NRF2-ARE,
and HIPPO. Ch-e tumors demonstrated increased expression
of genes involved in oxidative phosphorylation, while the clear
cell RCC-enriched subtypes and the P.CIMP-e subtype all
showed low expression (Figure 5A), consistent with these tumors
being characterized by a Warburg-like metabolic shift to aded Fisher’s exact test) of nonsilent mutation events for each gene within any
enes implicated in cancer, either in this present study or elsewhere as indicated
(one-sided Fisher’s exact test) of nonsilent mutation events for each pathway
es), numbers of structural variants (i.e., genomic rearrangements) by genomic
, 75%, and 95%.
ents are represented in circos plot; blue lines, intra-chromosomal events; red
g 759 RCC cases evaluated) represent genes differentially expressed between
d genes and associated annotation by Gene Ontology (GO) are indicated.
s
Figure 4. Widespread Molecular Changes Associated with Chromatin Modifier Mutation
(A) The MEMo algorithm identified a pattern of mutually exclusive gene alterations (somatic mutations and copy alterations) targeting multiple components of the
SWI/SNF complex and histone acetyltransferases EP300 and CREBBP (269 cases altered, 266 with exome data, or 31%). The alteration frequency for clear cell-
enriched and papillary-enriched RCC subgroups (CC-e and P-e, respectively) is shown for each gene in the pathway diagram.
(B) Global consequences of mutation in epigenetic modifiers PBRM1, SETD2, and BAP1. Yellow-blue heatmap represents genes differentially expressed with
nonsilent somaticmutation ofPBRM1 in both clear cell-enriched and papillary-enriched RCCsubgroups (p < 0.001 in at least one of the two groups and p < 0.01 in
the other group, t test; FDR < 1%), with mutation of SETD2 in both subgroups, or with mutation of BAP1 in both subgroups. Purple-cyan heatmap represents
(legend continued on next page)
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glycolysis dependent metabolism. These differences could
reflect differences in the levels of mitochondrial biosynthesis be-
tween the subtypes, also supported by analysis of mtDNA copy
numbers by subtype (Figure S5A). Furthermore, differences be-
tween CC-e.3 tumors and CC-e.2 tumors reflected evidence of a
metabolic shift previously associated with aggressive clear cell
RCC (Figure S5B) (Cancer Genome Atlas Research Network,
2013). Based on analysis of proteomic data, a MAP kinase
pathway phosphoprotein signature was higher in clear cell-en-
riched RCC subtypes, as compared to both chromophobe-
and papillary-enriched RCC subtypes (Figure 5B). The P.CIMP-e
subtype showed elevated NRF2-ARE pathway compared to the
other papillary-enriched RCC subtypes, in terms of both expres-
sion of NQO1 (a critical effector of pathway activation) and
NFR2-ARE transcriptional signatures (Figure 5C). P.CIMP-e
also showed loss of tumor suppressor NF2 coupled with an in-
crease in downstream transcriptional targets (Figure 5D). In gen-
eral, the above pathway-level alterations characterizing the clear
cell-enriched RCC subtypes were also evident when examining
the individual key genes involved (Figure 5E). While transcrip-
tional targets of NFR2-ARE and HIPPO pathways showed
elevated expression in P.CIMP-e tumors, mutations involving
key pathway-related genes, with the exception of NF2, were
spread across several subtypes and did not account for the
observed transcriptional differences among subtypes (Figures
3A and 5F).
Based on analysis of proteomic data, both the PI3K/AKT and
mTOR pathways were elevated in both clear cell-enriched and
papillary-enriched RCC genomic subtypes versus Ch-e subtype
(Figure 6A), though Ch-e showed lower PTEN protein expression
as compared to other RCC (Figures 6A and S6). Additionally,
unsupervised pathway analysis using the MEMo algorithm iden-
tified mutually exclusive patterns of alterations targeting multiple
components of the PI3K/AKT/mTOR pathway in 29% of RCC
cases (Figure 6B), with, for example, alterations involving the
clear cell-enriched RCC subtypes including amplification of
5q35.3 (involving GNB2L1, SQSTM1, and FGFR4) (Sato et al.,
2013; Cancer Genome Atlas Research Network, 2013) and alter-
ations involving papillary-enriched RCC subtypes including mu-
tation or amplification ofMET. On average, RCC cases within the
MEMo module showed higher PI3K/AKT/mTOR signaling than
the uninvolved cases (Figure 6B).
Modulation of immune checkpoint pathways represents a
mechanism by which some tumors may avoid elimination by
the immune system. We surveyed our RCC cases for expressiongenomic loci (selected from the top 2,000 most variable loci in Figure 2A, acro
mutation of PBRM1 in both clear cell-enriched and papillary-enriched RCC subgro
or with mutation of SETD2 in both subgroups. Cases manifesting gene transcript
the bottom (‘‘SETD2 mut. sig.’’ and ‘‘BAP1 mut. sig.,’’ respectively). Numbers of
(C) For clear cell-enriched and papillary-enriched genomic subtypes combined,
mutation, SETD2 mutation-associated gene signature pattern, and BAP1 mut
log-rank test, adjusting for differences between clear cell-enriched and papillary
data available.
(D) For CpG islandmethylation probes significantly increasedwithmutation of a sp
papillary-enriched cohorts, based on cases profiled on 450K arrays), significant n
(p < 0.01, t test, both clear cell-enriched and papillary-enriched cohorts). Enrichme
showing coordinate methylation and expression changes between SETD2 mutan
See also Figure S4 and Table S6.
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including PD1 and PDL1 genes (Figure 7B). Clear cell-associated
RCC subtypes had relatively high expression of several genes
representing targets for immunotherapy (Figure 7A), including
PDCD1 (PD1), CD247 (CD3), PDCD1LG2 (PDL2), CTLA4
(CD152), TNFRSF9 (CD137), and TNFRSF4 (CD134). In addition,
analysis of gene expression signatures (Bindea et al., 2013) and
of DNA methylation signatures suggested greater levels of im-
mune cell infiltrates within clear cell RCC relative to other RCC
types (Figures 7A and S7A–S7C), including T cells in particular.
Within clear cell-enriched RCC genomic subtypes, differential
expression of specific checkpoint-related genes was observed,
in particular involving differences between CC-e.3 and CC-e.2
groups (representing more aggressive and less aggressive clear
cell RCC subsets, respectively) (Figures 7A and 7C). Compared
to CC-e.2, CC-e.3 showed increased promoter methylation of
miR-21 (MIR21) with corresponding decreased levels of the
miR-21 target PTEN (Figure 7C). In cancer, PTEN has an estab-
lished role in intrinsic cellular control of PD-L1 expression (Rit-
prajak and Azuma, 2015). Several genes—including PDCD1,
CTLA4, and TLR9—were associated with worse patient survival
within clear cell RCC-associated cases (Figure 7D); PDL1
expression was correlated with better patient survival, though
this association was confounded by copy loss of 9p region asso-
ciated with aggressive clear cell RCC and worse prognosis
(El-Mokadem et al., 2014).
DISCUSSION
Using an extended dataset of samples not present in the initial
TCGA marker studies, we were able to make novel findings in
this present study, through comparisons and contrasts across
the major histologic types of RCC. In addition to providing a uni-
fiedmolecular view of the entire TCGARCCcohort, observations
made in this study include the following: (1) association of papil-
lary RCC with proximal nephron as its site of origin by global
molecular profile; (2) identification of a subset of RCC showing
widespread DNA hypermethylation patterns, having associa-
tions with more aggressive disease (consistent with the results
of the previous KIRC study, which evaluated total global methyl-
ation as a continuous variable and associated it with increasing
grade and stage in clear cell RCC); (3) identification of a poten-
tially novel RCC subtype (the ‘‘mixed’’ subtype) with patterns
distinct from those of the threemajor RCC types (as well as those
of oncocytoma; Tan et al., 2010); (4) DNA copy-unstable patternsss 27K and 450K platforms) differentially methylated with nonsilent somatic
ups (p < 0.001 in at least one of the two groups and p < 0.01 in the other group)
ion signatures related to SETD2mutation or BAP1mutation are denoted along
cases represent RCC with both exome and RNA-sequencing data.
differences in patient overall survival associated with SETD2 mutation, BAP1
ation-associated gene signature pattern, respectively. p values by stratified
-enriched cohorts. Numbers of cases represent patients from (A) with survival
ecific chromatinmodifier gene (p < 0.001, t test, for both clear cell-enriched and
umbers of associated genes showed a corresponding decrease in expression
nt p values by one-sided Fisher’s exact test. Corresponding patterns for genes
t versus wild-type tumors are shown.
s
Figure 5. Differentially Active Pathways across RCC Genomic Subtypes
(A) Differential aggregate expression of mRNAs (using normalized values) involved in oxidative phosphorylation among the genomic subtypes.
(B) Differential MAP Kinase protein signaling among subtypes (by reverse-phase protein array [RPPA], average of phospho-SHC or pSHC, pRAF, pMEK, pERK,
pSRK, pYB1, pP38, pJNK, and pJUN).
(C) Differential mRNA expression of NRF2-ARE pathway marker NQO1 (left, normalized values) and differential aggregate expression of NRF2-ARE transcrip-
tional targets (right).
(D) Differential protein expression of HIPPO pathway regulator NF2 (left) and differential aggregate expression of downstream YAP1 transcriptional targets (right).
(E) Differential expression patterns of clear cell-enriched RCC subtypes (‘‘CC-e’’) versus Ch-e tumors in metabolism- and MAPK-related pathways.
(F) Differential expression patterns of P.CIMP-e tumors versus P-e.1a/1b tumors in NRF2-ARE- and HIPPO-related pathways. Percentages denote nonsilent
mutation frequency across all RCC cases. For parts A-F, p values for indicated comparisons by t test on log-transformed data. Boxplots represent 5%, 25%,
50%, 75%, and 95%. Normal kidney samples were not represented on RPPA platform.
See also Figure S5.and CDKN2A loss being associated with more aggressive clear
cell as well as papillary RCC; (5) increased levels of genomic
rearrangement in the P.CIMP-e subtype (associated with hered-
itary papillary RCC) as compared to other RCC subtypes; (6)
distinct global molecular patterns associated with TFE3 gene fu-
sions in RCC; (7) coordinate gene expression and DNA methyl-
ation changes associated with chromatin modifier mutation in
both clear cell and papillary RCC; (8) patterns of mutual exclu-
sivity in genomic alterations involving SWI/SNF and PI3K/AKT/
mTOR pathways that span both clear cell and papillary RCC;
(9) transcriptional and proteomic patterns involving oncogenicCellpathways as examined across all RCC subtypes; and (10) a
comprehensive view of the immune checkpoint pathway in RCC.
This study provides a multi-platform-based molecular view of
RCC. Both the molecular view and the more conventional histol-
ogy-based view would offer insights, and in this study, we find
the two to bemostly concordant, with themolecular data broadly
grouping together samples with the same histologic classifica-
tion. Given the wide diversity represented by RCC, some cases
may be difficult to characterize by pathology or by molecular
profiling. Limitations with the pathology-based diagnoses of
TCGA RCC cases in particular has been acknowledgedReports 14, 2476–2489, March 15, 2016 ª2016 The Authors 2485
Figure 6. PI3K/AKT/mTOR Pathway-Related Alterations across RCC Genomic Subtypes
(A) Left: boxplots of protein signaling (by RPPA) for PI3K-AKT (sum of normalized values for pAkt, pGSK3, pPRAS40, and pTSC2, minus total PTEN) and mTOR
(sum of pmTOR, p4EBP1, pP70S6K, and pS6) across the RCC genomic subtypes. Right: differential protein expression patterns (p% 0.01) involving the PI3K/
AKT/mTOR pathway, comparing papillary RCC-enriched subtypes (‘‘P-e’’) with Ch-e. p values by t test. Boxplot represents 5%, 25%, 50%, 75%, and 95%.
(B) For the PI3K/AKT/mTOR pathway, the MEMo algorithm identified a pattern (involving 29% of RCC cases) of mutually exclusive gene alterations (somatic
mutations and copy alterations) targeting multiple components, including three genes from the recurrent amplicon on 5q35.3. The alteration frequency (CC-e,
clear cell RCC-enriched subtypes; P-e, papillary RCC-enriched subtypes) and inferred alteration type (blue for inactivation, and red for activation) is shown for
each gene in the pathway diagram. p values (by t test) compare RPPA scores for PI3K/AKT and mTOR between cases involved versus uninvolved in the MEMo
module (excluding mixed and Ch-e tumors).
See also Figure S6.elsewhere (Davis et al., 2014; Cancer Genome Atlas Research
Network, 2013, 2015), including the primary diagnosis being
made by different pathologists at their respective tissue source
sites, with often only a single representative slide being made
available to TCGA investigators for any systematic re-review.
On the other hand, molecular subtyping for some RCC cases
can also vary, depending on the analytical techniques or cut
points applied. Our nine major genomic subtypes may not
necessarily capture all of the molecular diversity existing within
RCC, and future studies, e.g., those incorporating larger
numbers of RCC cases, could uncover additional relevant sub-
types within the existing classifications.
The global molecular profile of a cancer reflects the influence
of cell of origin, somatic alterations, and microenvironment.
RCCs are thought to arise from a variety of specialized cells
located along the length of the nephron, giving rise to the
diversity of histologic RCC types (Cairns, 2010). In this study, his-
tologic type is a primary factor in separating RCC tumors into
molecular classes by unsupervised approaches. Within the
RCC histologic types, we could observe further levels of molec-2486 Cell Reports 14, 2476–2489, March 15, 2016 ª2016 The Authorular diversity, involving somatic alterations of genome and epige-
nome compartments. RCC can demonstrate significant regional
genomic heterogeneity (Gerlinger et al., 2012), which may influ-
ence the aggregate molecular patterns in our study, including
the observed genomic subtypes with patterns intermediate be-
tween two distinct subtypes (e.g., CC-e.1 or P.e.1b). Within a
set of tumors sharing a common cellular or genetic background,
somatic alterations involving specific genes (e.g., chromatin
modifiers) can result in a consistent set of downstream alter-
ations.While clear cell and papillary RCC tumors harboring chro-
matin modifier mutations did not group together when carrying
out unsupervised clustering of molecular profiles, when
comparing mutated tumors to wild-type tumors within either
clear cell-associated or papillary-associated RCC genomic sub-
types, similar sets of geneswere found altered in each case, sug-
gesting that these chromatin modifier mutations influence
molecular profiles independently of 3p LOH or VHL inactivation.
The molecular differences represented by our RCC genomic
subtypes would point to pathways having implications for tar-
geted therapy, including MET (Choueiri et al., 2013), Hippos
Figure 7. Immune-Checkpoint-Related Differences across RCC Genomic Subtypes
(A) Heatmaps of differential expression across RCC cases for genes encoding immunotherapeutic targets (top), gene expression-based signatures of immune
cell infiltrates (middle, LCK protein by RPPA), and DNAmethylation-based signatures of T cell infiltrates (bottom). Asterisk indicates features significantly higher in
CC-e.3 versus CC-e.2 tumors (p < 0.01, t test). TREG cells, regulatory T cells; TGD cells, T gamma delta cells; Tcm cells, T central memory cells; Tem cells,
T effector memory cells; Tfh cells, T follicular helper cells; NK cells, natural killer cells; DC, dendritic cells; iDC, immature DCs; aDC, activated DCs; P-DC,
plasmacytoid DCs; APM1/APM2, antigen presentation on MHC class I/class II, respectively.
(B) Differential mRNA expression (normalized) of immune checkpoint targets PDCD1 (PD1, left) and CD274 (PDL1, right) among the genomic subtypes. Boxplot
represents 5%, 25%, 50%, 75%, and 95%. p values by t test.
(C) Differential expression patterns of CC-e.3 tumors versus CC-e.2 tumors related to interactions between T cells and antigen-presenting cells (including tumor
cells). p values by t test.
(D) Differences in patient overall survival associated with expression of PDCD1 (PD1) mRNA (left), expression of CTLA4 (CD152) mRNA (middle), and expression
of TLR9mRNA (right). For CTLA4 and TLR9, p values by log-rank test evaluating differences among top, bottom, and middle tertiles of expression; for PDCD1,
p value by log-rank test comparing cases in the bottom third of expression with the remaining cases.
See also Figure S7.(Johnson and Halder, 2014), MAP kinase (Santoni et al., 2014),
NRF2-ARE (Sporn and Liby, 2012), PI3K/AKT/mTOR (Motzer
et al., 2008), metabolism, and immune checkpoint (Harshman
et al., 2014; Motzer et al., 2015). While analysis of somatic muta-
tions could implicate the involvement of the above pathways
within subsets of RCC, expression data would also indicate
that a hyperactive pathway would not necessarily be limited to
tumors harboring specific mutations but could represent a hall-
mark of a specific RCC genomic subtype. In recent clinical trial
studies, blocking antibody agents against the inhibitory pro-
grammed death-1 (PD-1) pathway have shown great promise
in treating RCC (Harshman et al., 2014; Motzer et al., 2015).
Other immune checkpoint genes overexpressed in clear cell
RCC cancer cells or clear cell RCC-associated immune infil-
trates, including CTLA4 and PDL1 gene, also represent potential
immunotherapy targets (Yang et al., 2007). TCGA data would
suggest an intriguing hypothesis that specific subtypes of RCC
would be most responsive to targeted immune checkpoints
versus increasing T cell activation.CellThe entire TCGA RCC dataset as presented here, now with
more extensive molecular annotation of the cases being pro-
vided as a result of this study (Table S1), will continue to serve
as a resource for future studies to better understand the mo-
lecular basis of RCC subtypes in the context of other diseases.
Given the potential for a fraction of RCC cases within TCGA to
have a histologic type differing from that of the sample’s proj-
ect designation, the annotation of cases by genomic subtype
can greatly inform future studies utilizing these data. Our mo-
lecular subtype discovery yields subgroups of RCC recogniz-
able in terms of histologic typing and of results from previous
molecular studies, in addition to defining the molecular attri-
butes and associated patient survival of these subgroups. An
important avenue of future work will be to identify those
disease subtype markers considered most relevant from the
standpoint of therapy and those with clear potential for
application in the clinical setting, e.g., using immunohisto-
chemistry or other methods that pathologists may have at their
disposal.Reports 14, 2476–2489, March 15, 2016 ª2016 The Authors 2487
EXPERIMENTAL PROCEDURES
The results published here are based upon data generated by TCGA
Research Network. With informed consent, biospecimens were collected
from newly diagnosed patients with RCC undergoing surgical resection.
Using a co-isolation protocol, DNA and RNA were purified. In total, 894
RCC cases were assayed on at least one molecular profiling platform
(Table S1), which included (1) RNA sequencing, (2) DNA methylation arrays,
(3) miRNA sequencing, (4) Affymetrix SNP arrays, (5) whole-exome
sequencing, (6) whole-genome sequencing, and (7) reverse-phase protein
array (RPPA). As described above and in Supplemental Experimental Proce-
dures, both single-platform analyses and integrated cross-platform analyses
were performed.
ACCESSION NUMBERS
Sequence files are available from CGHub (https://cghub.ucsc.edu/). All other
molecular, clinical, and pathological data are available through the TCGA
Data Portal (https://tcga-data.nci.nih.gov/tcga/).
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